The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
†In PALACE 1-3, 76.4% of patients were biologic-naïve, as mandated by study protocol.
‡In psoriatic arthritis trials, combination therapy included concomitant use of one or more of the following: methotrexate, sulfasalazine, or leflunomide, low-dose oral corticosteroid and/or NSAID.
ACTIVE, Accessing Apremilast Monotherapy in a Clinical Trial of Biologic-Naïve Patients with Psoriatic Arthritis; csDMARD, conventional synthetic disease-modifying antirheumatic drug; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.